Lerociclib (G1T38) is a novel, potent, orally bioavailable and selective inhibitor of CDK4/6, with IC50s of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.

SR-4835 (SR4835) is a novel highly selective dual inhibitor of CDK12 and CDK13 with anticancer activity.

AT-7519 diHCl is a novel and potent multi-CDK (cyclin-dependent kinase) inhibitor for Cdk1/cyclin B, Cdk2/Cyclin A, Cdk3/Cyclin E, Cdk4/Cyclin D1, Cdk5/p35, and Cdk6/Cyclin D3 with IC50s of 210, 47, 100, 13, 170, and<10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

Abemaciclib (formerly known as LY2835219; trade name: Verzenio) is a potent and selective, and orally bioavailable dual inhibitor of CDK4 (cyclin-dependent kinase) and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively.

FIT-039 (FIT039) is an oral, selective and ATP-competitive CDK9 (cyclin-dependent kinase 9) inhibitor with antiviral activity. .

Dinaciclib (formerly known as PS-095760, SCH727965; PS 095760; SCH 727965) is a novel, selective and potent cyclin-dependent kinases (CDK) inhibitor with potential antineoplastic activity.

Ribociclib HCl (formerly also known as LEE-011, NVP-LEE011; Kisqali), the hydrochloride salt of Ribociclib, is an orally bioavailable CDK4/6 (cyclin-dependent kinase) inhibitor (IC50s = 10 nM and 39 nM) approved in March 2017 by FDA to treat postmenopausal women with a type of advanced breast cancer.

(rel)-MC180295 is a novel, potent and selective CDK9-Cyclin T1 inhibitor with an IC50 of 5 nM and with broad anti-cancer activity in vitro.

BI-1347 is a novel, potent and selective CDK8 inhibitor with an IC50 of 1.1 nM.

Ribociclib succinate (LEE011, NVP-LEE-011; LEE-011, NVP-LEE011; Kisqali), the succinate salt of Ribociclib, is a CDK4/6 (cyclin-dependent kinase) inhibitor (IC50s = 10 nM and 39 nM) approved in March 2017 by FDA for the treatment of breast cancer.